Cara Therapeutics

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Cara Therapeutics reports strong Q1 sales, optimistic about pipeline growth

Cara Therapeutics demonstrated strong sales performance in Q1 2023, driven by the successful launch of KORSUVA injection in the U.S. and the international rollout of Kapruvia in Europe. While facing financial challenges, the company remains optimistic about its pipeline and market opportunities. Proactive measures, such as exploring non-diluted financing, reflect a strategic approach to financial management.

CARA reports strong Q2 sales, faces CMS payment challenges

CARA's Q2 2023 performance reflects strong sales for KORSUVA and Kapruvia, but high R&D and G&A expenses impact overall financials. The company faces challenges related to the CMS proposed payment adjustment but remains confident in its product portfolio. Opportunities lie in addressing CMS concerns and exploring non-dilutive funding sources.

Cara Therapeutics reports strong Q3 earnings and outlines growth opportunities

Cara Therapeutics' Q3 earnings call showcased strong financial performance, strategic focus on late-stage programs, and promising growth opportunities. While challenges in enrollment metrics and commercial strategy were discussed, the company's detailed responses and potential market opportunities indicate a positive outlook. The non-dilutive financing deal and progress in late-stage pipeline programs position Cara for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Editas Medicine

Genfit - ADR

They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.

3 Top Small-Cap Biotech Stocks for Aggressive Investors

The pharma company announced full-year 2018 operating results and reiterated the road map for the year ahead.

Here's Why Cara Therapeutics Stock Rose as Much as 13.9% Today

News for Cara Therapeutics Stock (CARA)